RNAi therapeutics: Principles, prospects and challenges

被引:667
|
作者
Aagaard, Lars [1 ]
Rossi, John J. [1 ]
机构
[1] City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol, Duarte, CA 91010 USA
关键词
siRNA; shRNA; RNAi; RNA interference; antisense; miRNA; RISC;
D O I
10.1016/j.addr.2007.03.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other antisense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression. Despite the excitement about this remarkable biological process for sequence specific gene regulation, there are a number of hurdles and concerns that must be overcome prior to making RNAi a real therapeutic modality, which include off-target effects, triggering of type I interferon responses, and effective delivery in vivo. This review discusses mechanistic aspects of RNAi, the potential problem areas and solutions and therapeutic applications. It is anticipated that RNAi will be a major therapeutic modality within the next several years, and clearly warrants intense investigation to fully understand the mechanisms involved. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:75 / 86
页数:12
相关论文
共 50 条
  • [21] RNAi therapeutics: An update on delivery
    Nguyen, Thu
    Menocal, Ellen M.
    Harborth, Jens
    Fruehauf, Johannes H.
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2008, 10 (02) : 158 - 167
  • [22] RNAi therapeutics in peripheral neuropathies
    Vita, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 971 - 971
  • [23] The Business of RNAi Therapeutics in 2012
    Haussecker, Dirk
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2012, 1
  • [24] RNAi therapeutics for the lowering of cholesterol
    Fitzgerald, Kevin
    Frank-Kamenetsky, Maria
    Zimmermann, Tracy S.
    Horton, Jay
    Akinc, Akin
    Bramlage, Birgit
    Bumcrot, David
    Harborth, Jens
    John, Matthias
    Kotelianski, Victor
    Manoharan, Muthiah
    Maier, Martin
    Nechev, Lubomir
    Racie, Timothy
    Roehl, Ingo
    Seiffert, Stephan
    Shanmugam, Sumi
    Soutschelk, Jurgen
    Toudjarska, Ivanka
    Vormocher, Hans-Peter
    Zedalis, William
    CIRCULATION, 2007, 116 (16) : 105 - 105
  • [25] RNAi Therapeutics: The Teenage Years
    Perkel, Jeffrey M.
    BIOTECHNIQUES, 2012, 52 (06) : 355 - 357
  • [26] RNAi Therapeutics in Autoimmune Disease
    Pauley, Kaleb M.
    Cha, Seunghee
    PHARMACEUTICALS, 2013, 6 (03): : 287 - 294
  • [27] NOVARTIS EXITS RNAI THERAPEUTICS
    不详
    CHEMICAL & ENGINEERING NEWS, 2014, 92 (16) : 17 - 17
  • [28] Translating bacteriophage-derived depolymerases into antibacterial therapeutics:Challenges and prospects
    Honglan Wang
    Yannan Liu
    Changqing Bai
    Sharon Shui Yee Leung
    Acta Pharmaceutica Sinica B, 2024, 14 (01) : 155 - 169
  • [29] Translating bacteriophage-derived depolymerases into antibacterial therapeutics: Challenges and prospects
    Wang, Honglan
    Liu, Yannan
    Bai, Changqing
    Leung, Sharon Shui Yee
    ACTA PHARMACEUTICA SINICA B, 2024, 14 (01) : 155 - 169
  • [30] Review of Microneedle Technology for Targeted Therapeutics in Vitiligo: Design Principles, Application Prospects
    Yu, Yihui
    Li, Wei
    Li, Qian
    Liu, Wenyan
    Zhang, Sanquan
    Zhang, Xibao
    Liang, Jingyao
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 4901 - 4914